abstract |
The invention provides specific quinoxalines and azaquinoxalines of formula (I), and their pharmaceutically acceptable salts, wherein J 1 , J 2 , R 1 , R 2 , R 3 , R 22 , R a , R b , R c , R d , X, Y, b, n and q are as herein defined in . The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds to treat diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH 2 function. |